	US 11,897,967 B2
	*Humanized anti-MUC1 antibodies**
Cynthia Bamdad, Waltham, MA (US); and Benoit Smagghe, Waltham, MA (US)
Assigned to MINERVA BIOTECHNOLOGIES CORPORATION, Waltham, MA (US)
Filed by Minerva Biotechnologies Corporation, Waltham, MA (US)
Filed on Aug. 4, 2022, as Appl. No. 17/817,515.
Application 17/817,515 is a continuation of application No. 15/549,942, granted, now 11,746,159, previously published as PCT/US2016/017422, filed on Feb. 10, 2016.
Claims priority of provisional application 62/114,526, filed on Feb. 10, 2015.
Prior Publication US 2023/0279142 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/3092 (2013.01) [A61K 39/00117 (2018.08); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01)]

30 Claims

1. A chimeric antigen receptor (CAR) comprising

(a) an anti-MUC1* antibody fragment wherein the anti-MUC1* antibody fragment comprises a heavy chain variable region and a light chain variable region that has complementarity determining regions (CDRs) in the heavy chain variable region and the light chain variable region as follows:

CDR1 heavy chain SEQ ID NO: 123,

CDR1 light chain SEQ ID NO: 173,

CDR2 heavy chain SEQ ID NO: 127,

CDR2 light chain SEQ ID NO: 177,

CDR3 heavy chain SEQ ID NO: 131, and

CDR3 light chain SEQ ID NO: 181; and

(b) a T cell receptor co-stimulatory domain.